Planet Labs (PL) Q2 2027 Earnings Call Transcript

Planet Labs reported fiscal Q2 2027 revenue of $116.1 million, up 58% year over year, with non-GAAP gross margin of 59% and adjusted EBITDA of $13.9 million, materially exceeding expectations on satellite-services hardware handovers. The company raised the low end of full-year revenue guidance to $430 million-$441 million, implying 40%-43% growth, and lifted adjusted EBITDA guidance to $3 million-$10 million. Backlog rose 11% to $814.9 million, cash and short-term investments reached $865.4 million following $120 million of ATM equity issuance, and management cited a $4 billion satellite-services pipeline, including more than $1 billion of near-term opportunities. Growth investments are increasing, with full-year CapEx guided to $100 million-$115 million for manufacturing expansion and Pelican/Owl next-generation satellite fleets; Q3 is expected to post an adjusted EBITDA loss of $1 million-$6 million.

Analysis

PL’s investable change is the shift from a pure imagery subscription vendor toward sovereign satellite capacity plus higher-value analytics. That improves contract size and strategic relevance, but it also replaces smooth SaaS-like recognition with milestone-driven revenue, making the next 1-3 quarters vulnerable to apparent “misses” despite intact demand. The key underwriting variable is conversion of qualified sovereign pipeline into signed awards, not the headline pipeline itself; procurement cycles, export approvals, and customer financing can turn a quarters-based opportunity set into a multi-year sales cycle.

The strongest second-order beneficiary is likely Germany/Europe’s space-industrial ecosystem, including launch and component suppliers, as sovereign procurement increasingly values local manufacture and launch. Conversely, PL’s daily-monitoring advantage pressures high-resolution tasking specialists such as BKSY and Maxar/Advent-backed geospatial offerings in broad-area surveillance, but it does not eliminate the need for SAR, RF, or specialized analytics; customers may favor multi-sensor integrators rather than a single optical-data vendor.

The balance sheet removes near-term financing risk, but recent equity issuance establishes a practical overhang: management has demonstrated willingness to fund capacity ahead of contracted revenue. Incremental CapEx must produce either durable dedicated-capacity contracts or materially higher ARPU from next-generation imagery; otherwise, EBITDA expansion will lag revenue growth and the stock’s growth multiple is exposed. Near-term launch congestion is an operational risk, while a delayed government budget cycle or failed/underperforming next-generation constellation would be more consequential over 6-18 months.

Consensus may be over-extrapolating the latest margin and growth print. The more constructive contrarian view is that the recurring-data base and analytics upsell can absorb satellite-services volatility, but that requires commercial AI monetization—not just beta engagement—to become visible by the next two earnings cycles. Treat management’s sole-source and pricing-power claims as customer-specific until renewal duration, ACV, and gross-margin contribution validate them.

Key Decisions for Investors

• Maintain a tactical long PL only on post-earnings weakness or after confirmation of a material sovereign award; target a 6-12 month horizon. Upside case is multiple expansion if signed backlog and recurring analytics growth offset milestone volatility; exit/reduce if FY revenue guidance is cut or annual adjusted free cash flow turns negative after CapEx.
• Use a defined-risk bullish structure rather than chasing spot: buy 6-9 month PL call spreads after assessing implied volatility, sized against a 25-35% drawdown. The catalyst is conversion of near-term sovereign opportunities or evidence that Owl/Pelican supports higher pricing; the primary risk is dilution, launch delay, or a Q3/Q4 revenue-recognition reset.
• Watch-list a relative long PL / short BKSY basket over 6-18 months only if PL discloses further sole-source broad-area monitoring wins and BKSY lacks comparable contracted demand. This expresses differentiation in revisit-rate/archive analytics while reducing sector beta; invalidate if BKSY secures major defense awards or PL’s backlog conversion slows.
• Do not underwrite the AI narrative until management discloses general-availability timing, pricing, paid-user conversion, or measurable commercial ACV contribution. Set an alert for the next two reports: commercial growth acceleration with stable net retention would justify increasing exposure; continued pilot-heavy commentary would argue for treating AI as option value only.